TY - JOUR
T1 - Creating in Vitro Three-Dimensional Tumor Models
T2 - A Guide for the Biofabrication of a Primary Osteosarcoma Model
AU - Chow, Thomas
AU - Wutami, Ilycia
AU - Lucarelli, Enrico
AU - Choong, Peter F.
AU - Duchi, Serena
AU - Di Bella, Claudia
N1 - Funding Information:
This work was supported by St Vincent's Hospital (Melbourne) Research Endowment Fund 2019_2020_Duchi. C.D.B. holds an NHMRC Early Leadership Investigator Grant for musculoskeletal bioengineering. P.F.C. holds an NHMRC Practitioner Fellowship (1154203).
Funding Information:
This work was supported by St Vincent’s Hospital (Melbourne) Research Endowment Fund 2019_2020_Duchi. C.D.B. holds an NHMRC Early Leadership Investigator Grant for musculoskeletal bioengineering. P.F.C. holds an NHMRC Practitioner Fellowship (1154203).
Publisher Copyright:
© 2021, Mary Ann Liebert, Inc., publishers.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Osteosarcoma (OS) is a highly aggressive primary bone tumor. The mainstay for its treatment is multiagent chemotherapy and surgical resection, with a 50-70% 5-year survival rate. Despite the huge effort made by clinicians and researchers in the past 30 years, limited progress has been made to improve patient outcomes. As novel therapeutic approaches for OS become available, such as monoclonal antibodies, small molecules, and immunotherapies, the need for OS preclinical model development becomes equally pressing. Three-dimensional (3D) OS models represent an alternative system to study this tumor: In contrast to two-dimensional monolayers, 3D matrices can recapitulate key elements of the tumor microenvironment (TME), such as the cellular interaction with the bone mineralized matrix. The advancement of tissue engineering and biofabrication techniques enables the incorporation of specific TME aspects into 3D models, to investigate the contribution of individual components to tumor progression and enhance understanding of basic OS biology. The use of biomaterials that mimic the extracellular matrix could also facilitate the testing of drugs targeting the TME itself, allowing a larger range of therapeutics to be tested, while averting the ethical implications and high cost associated with in vivo preclinical models. This review aims at serving as a practical guide by delineating the OS TME ("what it is like") and, in turn, propose various biofabrication strategies to create a 3D model ("how to recreate it"), to improve the in vitro representation of the OS tumor and ultimately generate more accurate drug response profiles.
AB - Osteosarcoma (OS) is a highly aggressive primary bone tumor. The mainstay for its treatment is multiagent chemotherapy and surgical resection, with a 50-70% 5-year survival rate. Despite the huge effort made by clinicians and researchers in the past 30 years, limited progress has been made to improve patient outcomes. As novel therapeutic approaches for OS become available, such as monoclonal antibodies, small molecules, and immunotherapies, the need for OS preclinical model development becomes equally pressing. Three-dimensional (3D) OS models represent an alternative system to study this tumor: In contrast to two-dimensional monolayers, 3D matrices can recapitulate key elements of the tumor microenvironment (TME), such as the cellular interaction with the bone mineralized matrix. The advancement of tissue engineering and biofabrication techniques enables the incorporation of specific TME aspects into 3D models, to investigate the contribution of individual components to tumor progression and enhance understanding of basic OS biology. The use of biomaterials that mimic the extracellular matrix could also facilitate the testing of drugs targeting the TME itself, allowing a larger range of therapeutics to be tested, while averting the ethical implications and high cost associated with in vivo preclinical models. This review aims at serving as a practical guide by delineating the OS TME ("what it is like") and, in turn, propose various biofabrication strategies to create a 3D model ("how to recreate it"), to improve the in vitro representation of the OS tumor and ultimately generate more accurate drug response profiles.
KW - osteosarcoma
KW - preclinical in vitro models
KW - three-dimensional tumor models
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85111699931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111699931&partnerID=8YFLogxK
U2 - 10.1089/ten.teb.2020.0254
DO - 10.1089/ten.teb.2020.0254
M3 - Review article
C2 - 33138724
AN - SCOPUS:85111699931
VL - 27
SP - 514
EP - 529
JO - Tissue Engineering - Part B: Reviews
JF - Tissue Engineering - Part B: Reviews
SN - 1937-3368
IS - 5
ER -